共 45 条
[1]
Leoni V(2015)Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia Haematologica 100 295-299
[2]
Biondi A(2013)Optimal approach to treatment of patients with Philadelphia chromosome positive acute lymphoblastic leukemia: how to best use all the available tools Leuk Lymphoma 54 21-27
[3]
Ribera JM(2013)Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia Curr Hematol Malig Rep 8 98-108
[4]
Fielding AK(2006)Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia Clin Cancer Res 12 7374-7379
[5]
Zakout GA(2014)Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement Cancer 120 1002-1009
[6]
Soverini S(2007)Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain Haematologica 92 401-404
[7]
Colarossi S(2012)Ponatinib in refractory Philadelphia chromosome-positive leukemias N Engl J Med 367 2075-2088
[8]
Gnani A(2014)BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia Cancer Cell 26 428-442
[9]
Rosti G(2015)Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia Onco Targets Ther 8 1567-1574
[10]
Castagnetti F(2015)Mingzhi Zhang and Delong Liu. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia J Hematol Oncol 8 104-1648